Reportedly, VEGF signaling increases VEGFR2 expression and phosphorylation, and stimulates proliferation in VEGF-stimulated C2C12 cells (Supplementary Figure S2), and this might potentially reduce the effects of lenvatinib and L-carnitine in C2C12 cells
When the opposite occurs, it suggests either individual sensitivity, improper application, or interference from other factors
The absence of such evidence means that healthcare professionals cannot reliably predict how these drugs might interact, whether they would provide additive benefits, or what adverse effects might emerge from their concurrent use
For a medication protocol that requires titration management and side effect oversight, that's a real differentiator from platforms that offer one intake consultation and ship medication without ongoing support
Some people may need to avoid alcohol while using these medications unless their clinician says otherwise